WuXi Biologics has entered into an equity agreement with Pfizer China to acquire its state-of-the-art biologics manufacturing facilities as well as its labor force in Hangzhou, China. The transaction is expected to close in the first half of 2021, which will immediately boost the commercial Drug Substance (DS) and Drug Product (DP) capacities for WuXi Biologics to address surging manufacturing demands.   The state-of-the-art 50,000 sqaure meter facilities, GMP operational since 2018, includes ...